Effects of infliximab therapy on abdominal fat and metabolic profile in patients with Crohn's disease.
about
Bacterial translocation - impact on the adipocyte compartmentAdipokines and the role of visceral adipose tissue in inflammatory bowel diseaseAnti-inflammatory agents to treat or prevent type 2 diabetes, metabolic syndrome and cardiovascular disease.The Role of the Mesentery in Crohn's Disease: The Contributions of Nerves, Vessels, Lymphatics, and Fat to the Pathogenesis and Disease Course.Insights into the Role of Erysipelotrichaceae in the Human Host.Psoriasis comorbidities: complications and benefits of immunobiological treatmentUnresolved issues in biologic therapy for rheumatoid arthritis.Results of the 2nd part Scientific Workshop of the ECCO. II: Measures and markers of prediction to achieve, detect, and monitor intestinal healing in inflammatory bowel disease.Cooling down inflammation in type 2 diabetes: how strong is the evidence for cardiometabolic benefit?Metabonomics uncovers a reversible proatherogenic lipid profile during infliximab therapy of inflammatory bowel disease.An overview of lipid abnormalities in patients with inflammatory bowel diseaseLipid Profile in Inflammatory Bowel Disease Patients on Anti-TNFα Therapy.High prevalence of overweight and obesity in adults with Crohn's disease: associations with disease and lifestyle factors.Weight gain and tumour necrosis factor-alpha inhibitors in patients with psoriasis.Patients with Crohn's Disease with High Body Mass Index Present More Frequent and Rapid Loss of Response to Infliximab.Impact of biological therapy on body composition of patients with Chron's disease.Infliximab modifies mesenteric adipose tissue alterations and intestinal inflammation in rats with TNBS-induced colitis.
P2860
Q26852238-D499EF90-3258-4D41-8032-6AD6E53CEDC3Q28070229-DE49F002-85EC-4ED5-A2EB-D5815B20A576Q34444895-AFC07A0D-2DBB-489F-8CB2-1B926850A2C3Q34526079-DBA0FA6F-573D-4E48-91D5-0759716C3DC7Q35860778-6FD6D4B0-C843-4EE1-9401-C0DA9A7A9E14Q37540440-4C24D689-5ADF-48B4-9C64-D31E30906163Q37851001-7509393D-E0BA-48AE-AE3D-A1B30A258F6BQ37937183-F4655CB3-2034-44F2-9214-B9C62A6EE796Q38845570-8F02C120-A82B-4321-971E-74421119B58CQ42378152-2F58379C-8108-4151-9414-DEB16884F78FQ42406811-ADB73DF0-2989-4851-A186-E7F371A4792BQ42472908-9F19C04E-8381-4EF2-A9D3-059FDDB41074Q44608781-FD97589F-1A50-4555-98C2-116715E4EA52Q47203093-A540C752-DDD6-446C-89F2-D09C3310F046Q50496500-95021FD6-A0DB-45D6-901E-EC7EFCA183A1Q50525563-EF263E04-9221-4A3B-A914-15F1CD89687BQ54508822-887EF578-C39E-4A94-A8EB-70447B5AF3C0
P2860
Effects of infliximab therapy on abdominal fat and metabolic profile in patients with Crohn's disease.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Effects of infliximab therapy ...... patients with Crohn's disease.
@en
Effects of infliximab therapy ...... patients with Crohn's disease.
@nl
type
label
Effects of infliximab therapy ...... patients with Crohn's disease.
@en
Effects of infliximab therapy ...... patients with Crohn's disease.
@nl
prefLabel
Effects of infliximab therapy ...... patients with Crohn's disease.
@en
Effects of infliximab therapy ...... patients with Crohn's disease.
@nl
P2093
P2860
P50
P356
P1476
Effects of infliximab therapy ...... patients with Crohn's disease.
@en
P2093
Alain Duhamel
Catherine Fermont
Erika Parmentier-Decrucq
Gwenola Vernier-Massouille
Olivier Ernst
P2860
P304
P356
10.1002/IBD.20931
P577
2009-10-01T00:00:00Z